Elevated BACE1 predicts AD

Elevated B-secretase activity in the brain could be used as an indicator of Alzheimer's, according to data presented at the 2008 International Conference on Alzheimer's Disease, in Chicago, USA. The findings suggest BACE1 measured in cerebrospinal fluid may be a feasible biomarker for predicting AD in people with mild cognitive impairment, a transition stage between the cognitive changes of normal aging and the more serious problems of AD.

A team of scientists in Ireland and the USA measured BACE1 levels in CSF in 80 people with Alzheimer's, 59 with MCI and 69 healthy elderly controls at two independent, international research centers. MCI subjects showed highly increased levels of BACE1 activity when compared to HC and people with Alzheimer's.

BACE1 activity was significantly correlated with AB level. A subsequent validation study replicated these initial findings in a new and independent set of 41 people with Alzheimer's, 46 with amnestic MCI and elderly HC.